Trial reportThe European journal of health economics : HEPAC : health economics in prevention and care2018
Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy.
Trial report in The European journal of health economics : HEPAC : health economics in prevention and care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 5 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Cost-Effectiveness of Physiotherapy Services for Chronic Condition Management: A Systematic Review of Economic Evaluations Conducted Alongside Randomized Controlled Trials.Physiotherapy Canada. Physiotherapie Canada · 2024Pooled it
- Non-medical interventions to enhance return to work for people with cancer.The Cochrane database of systematic reviews · 2024Pooled it
- Cost-effectiveness of physical activity interventions in cancer survivors of developed countries: a systematic review.Journal of cancer survivorship : research and practice · 2021Pooled it
- Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data.Medicine and science in sports and exercise · 2020Pooled it
- Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer.Breast cancer research and treatment · 2019Pooled it
- Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Cost-effectiveness of peer-delivered physical activity promotion and maintenance programs for initially sedentary breast cancer survivors.Translational behavioral medicine · 2023Trial
- A cost-consequences analysis of the SAFE trial: a comparative, effectiveness trial evaluating high- versus low-supervision of an exercise intervention for women with breast cancer.Breast cancer (Tokyo, Japan) · 2023Trial
- Virtual Therapy Complementary Prehabilitation of Women Diagnosed with Breast Cancer-A Pilot Study.International journal of environmental research and public health · 2022Trial
- Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up.International journal of environmental research and public health · 2020Trial
- Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Trial
- Long-term effectiveness and cost-effectiveness of an 18-week supervised exercise program in patients treated with autologous stem cell transplantation: results from the EXIST study.Journal of cancer survivorship : research and practice · 2019Trial
- Cost-Effectiveness of the STEPS Work Participation Program Compared to Usual Care, for Cancer Survivors: An Economic Evaluation Alongside a Randomized Controlled Trial.Journal of occupational rehabilitation · 2026Article
- A qualitative exploration of patient and clinician needs and preferences for a physical activity intervention during breast cancer chemotherapy.BMC cancer · 2025Article
- Training gut and body: physical activity, diet, ASA and microbiota influence the outcome in gastrointestinal cancer survivors.Frontiers in nutrition · 2025Review
- Proximity to cancer rehabilitation and exercise oncology by geography, race, and socioeconomic status.Cancer · 2025Article
- The role of supervision and motivation during exercise on physical and mental health in older adults: a study protocol for a randomized controlled trial (PRO-Training project).BMC geriatrics · 2024Article
- Generic Health Utility Measures in Exercise Oncology: A Scoping Review and Future Directions.Current oncology (Toronto, Ont.) · 2023Article
- Prehabilitation to improve outcomes afteR Autologous sTem cEll transplantation (PIRATE): A pilot randomised controlled trial protocol.PloS one · 2023Article
- Cost evaluation of an exercise oncology intervention: The exercise in all chemotherapy trial.Cancer reports (Hoboken, N.J.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
introductionA home-based, low-intensity physical activity program (Onco-Move) and a supervised, moderate-to-high intensity, combined resistance and aerobic exercise program (OnTrack) have proven to be effective in maintaining physical fitness and reducing fatigue among breast cancer patients undergoing adjuvant chemotherapy. This study evaluated the cost-utility and cost-effectiveness of Onco-Move and OnTrack.
methodsA total of 230 patients were randomized to Onco-Move, OnTrack, or usual care (UC). Health outcomes included quality-adjusted life years (QALYs), general and physical fatigue, and physical fitness measured at baseline, end of chemotherapy, and 6-month follow-up. Societal costs included professional and informal health care, work absenteeism, and unpaid productivity costs. Cost data were based on 3-monthly questionnaires, supplemented by medication data obtained from pharmacies.
resultsOnco-Move is not likely to be cost-effective due to the relatively high willingness-to-pay necessary to reach reasonable probabilities of cost-effectiveness (QALY, general and physical fatigue). Incremental cost-effectiveness ratios for OnTrack compared to UC were €26,916/QALY, €788/1-point decrease in general fatigue and €1402/1-point decrease in physical fatigue. The probability of OnTrack being cost-effective ranged from 31% at a willingness-to-pay (WTP) of €0-79% at a WTP of €80,000/QALY, 97% at a WTP of €15,000/1-point decrease in general fatigue, and 86% at a WTP of €24,000/1-point decrease in physical fatigue. Both interventions had a low probability of being cost-effective for physical fitness. The probability of cost-effectiveness for both interventions was greater among compliant participants.
conclusionsOnco-Move is not likely to be cost-effective. Depending on the decision-makers' willingness-to-pay, OnTrack could be considered cost-effective in comparison with UC. Trial registration Clinical trial registration number of the Netherlands Trial Register-NTR2159.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.